Accordingly, EC.SENESCENCE.SIG predicts response to anti-PD-L1/PD-1 or anti-CTLA-4 immunotherapy in multiple cancer entities including lung cancer, gastric cancer, urothelial carcinoma, renal cell carcinoma, and basal-cell carcinoma. This evidence concerns the gene CTLA4 and renal cell carcinoma.